Syros Pharmaceuticals (NASDAQ:SYRS) shares traded up 5.4% during mid-day trading on Friday . The company traded as high as $11.26 and last traded at $11.10. 1,391,833 shares traded hands during mid-day trading, an increase of 505% from the average session volume of 229,979 shares. The stock had previously closed at $10.53.
A number of research analysts recently issued reports on the stock. ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 6th. BidaskClub raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 22nd. Wedbush reissued an “outperform” rating and issued a $13.00 price objective (up from $11.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, March 13th. Zacks Investment Research cut shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 16th. Finally, HC Wainwright reissued a “hold” rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday, March 14th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $21.13.
Get Syros Pharmaceuticals alerts:The company has a market capitalization of $416.35 million, a price-to-earnings ratio of -5.21 and a beta of -2.69.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Thursday, May 10th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.14). The business had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $3.41 million. analysts expect that Syros Pharmaceuticals will post -2.2 EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of SYRS. Two Sigma Advisers LP bought a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth $105,000. Adalta Capital Management LLC bought a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth $111,000. The Manufacturers Life Insurance Company grew its stake in shares of Syros Pharmaceuticals by 299.9% during the first quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock worth $168,000 after buying an additional 9,691 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth $191,000. Finally, Two Sigma Investments LP grew its stake in shares of Syros Pharmaceuticals by 80.3% during the fourth quarter. Two Sigma Investments LP now owns 21,197 shares of the company’s stock worth $206,000 after buying an additional 9,439 shares during the last quarter. 56.84% of the stock is currently owned by hedge funds and other institutional investors.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
No comments:
Post a Comment